Visceral Leishmaniasis remains a serious health problem in many developing countries with thousands of new cases recorded annually. Novel oral therapies are required as existing drugs are limited by their invasive means of administration long duration of treatment regimens. Moreover, with miltefosine as the sole oral drug, there are concerns of the eventual development of parasite resistance with its continuous use. In this study, we report on the in vitro and in vivo leishmanicidal effect of orally administered N-251 on the Leishmania donovani complex parasites in mice. Our results suggest that N-251 may be a potential lead compound for the development of a new oral chemotherapy against VL